Literature DB >> 29301793

O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth.

Heon Shin1,2, Hyun-Jeong Cha1, Keun Na1, Min Jung Lee1, Jin-Young Cho1, Chae-Yeon Kim1,2, Eun Kyung Kim3, Chang Moo Kang4, Hoguen Kim3, Young-Ki Paik5,2,6.   

Abstract

Posttranslational modifications of tumor suppressors can induce abnormal cell growth. Here, we identify site-specific O-GlcNAcylation as a critical block of FOXO3 that may abrogate a part of the p53 pathway, resulting in aberrant cancer cell growth. Of seven O-GlcNAcylation sites identified within the FOXO3 transactivation domain, we found that changes in O-GlcNAcylation at Ser284 modulated p21-mediated cancer cell growth. Overexpression of either O-GlcNAcylated FOXO3 (FOX-OV) or a Ser-to-Ala mutant (S284A) in PANC-1 cells indicated that S284 O-GlcNAc acts as a critical block of the FOXO tumor suppressor and induces proliferation in PANC-1 cancer cells by stimulating the MDM2-p53-p21 axis. Furthermore, S284A mutant cells lacking S284 O-GlcNAc and FOX-OV cells exhibited opposing MDM2-p53-p21 axis expression patterns at both the mRNA and protein levels. Thus, our study provides evidence to support a role for S284 O-GlcNAc as a critical block of FOXO3 to induce subsequent cancer cell growth via abrogation of the p53 regulatory circuit.Significance: These findings highlight a posttranslational mechanism for indirect abrogation of the p53 pathway, one that may occur with some frequency in human cancer cells. Cancer Res; 78(5); 1214-24. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29301793     DOI: 10.1158/0008-5472.CAN-17-3512

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

2.  Hyalinizing epithelioid tumors with OGT-FOXO fusions. A case report of a non-acral soft tissue mass harboring a novel FOXO4 gene rearrangement.

Authors:  Dianne Torrence; Lei Zhang; Yun-Shao Sung; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2021-02-02       Impact factor: 4.263

Review 3.  Real Talk: The Inter-play Between the mTOR, AMPK, and Hexosamine Biosynthetic Pathways in Cell Signaling.

Authors:  Gentry K Cork; Jeffrey Thompson; Chad Slawson
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-06       Impact factor: 5.555

Review 4.  Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.

Authors:  Tamás Nagy; Viktória Fisi; Dorottya Frank; Emese Kátai; Zsófia Nagy; Attila Miseta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

Review 5.  Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer.

Authors:  Neha M Akella; Lorela Ciraku; Mauricio J Reginato
Journal:  BMC Biol       Date:  2019-07-04       Impact factor: 7.431

6.  6q deletion is frequent but unrelated to patient prognosis in breast cancer.

Authors:  Patrick Lebok; Hannah Bönte; Martina Kluth; Christina Möller-Koop; Isabell Witzel; Linn Wölber; Peter Paluchowski; Christian Wilke; Uwe Heilenkötter; Volkmar Müller; Barbara Schmalfeldt; Ronald Simon; Guido Sauter; Luigi Terracciano; Rainer Horst Krech; Albert von der Assen; Eike Burandt
Journal:  Breast Cancer       Date:  2021-10-08       Impact factor: 4.239

Review 7.  Altered glycosylation in pancreatic cancer and beyond.

Authors:  Jan C Lumibao; Jacob R Tremblay; Jasper Hsu; Dannielle D Engle
Journal:  J Exp Med       Date:  2022-05-06       Impact factor: 17.579

8.  RUNX1 can mediate the glucose and O-GlcNAc-driven proliferation and migration of human retinal microvascular endothelial cells.

Authors:  Xindan Xing; Hanying Wang; Tian Niu; Yan Jiang; Xin Shi; Kun Liu
Journal:  BMJ Open Diabetes Res Care       Date:  2021-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.